In Brief: Summit Technology/Visx
This article was originally published in The Gray Sheet
Executive Summary
Summit Technology/Visx: Ophthalmic laser firms reach settlement of "all outstanding U.S. and international patent infringement disputes between them, including the infringement litigation in Delaware related to Summit's Azema patent and in Canada related to Visx's L'Esperance patents," the firms state. Under the terms of the agreement, the companies cross-license each other's foreign patents; in the U.S., Summit's Azema patent is contributed to Pillar Point Partners, a joint venture formed in 1992 to hold U.S. eye laser patents. An exchange of payments under the pact will result in a net $4.5 mil. payment to Summit...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.